INSERM UMR-S 1124, Paris, France.
Université Paris Cité, France.
FEBS Lett. 2022 Dec;596(24):3107-3123. doi: 10.1002/1873-3468.14465. Epub 2022 Aug 22.
The prevalence of metabolic diseases, such as obesity, diabetes, metabolic syndrome and chronic liver diseases among others, has been rising for several years. Epidemiology and mechanistic (in vivo, in vitro and in silico) toxicology have recently provided compelling evidence implicating the chemical environment in the pathogenesis of these diseases. In this review, we will describe the biological processes that contribute to the development of metabolic diseases targeted by metabolic disruptors, and will propose an integrated pathophysiological vision of their effects on several organs. With regard to these pathomechanisms, we will discuss the needs, and the stakes of evolving the testing and assessment of endocrine disruptors to improve the prevention and management of metabolic diseases that have become a global epidemic since the end of last century.
近年来，代谢性疾病（如肥胖症、糖尿病、代谢综合征和慢性肝病等）的患病率一直在上升。流行病学和机制毒理学（体内、体外和计算机模拟）最近提供了令人信服的证据，表明化学环境与这些疾病的发病机制有关。在这篇综述中，我们将描述导致代谢紊乱的生物过程，并提出一个综合的病理生理学观点，说明它们对多个器官的影响。对于这些病理机制，我们将讨论需要改进内分泌干扰物的测试和评估，以改善自上世纪末以来已成为全球性流行疾病的代谢性疾病的预防和管理，并讨论相关的利益关系。
